MicroRNA-205, a novel regulator of the anti-apoptotic protein Bcl2, is downregulated in prostate cancer

International Journal of Oncology

Volumn 43, Issue 1, 2013, Pages 307-314

  Verdoodt, Berlinda ^a   Neid, Matthias ^a   Vogt, Markus ^a   Kuhn, Viktoria ^a   Liffers, Sven Thorsten ^a   Palisaar, Rein Jüri ^b   Noldus, Joachim ^b   Tannapfel, Andrea ^a   Mirmohammadsadegh, Alireza ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Apoptosis; BCL2; Gleason grading; miR 205; Prostate carcinoma

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANDROGEN; MICRORNA 205; PROTEIN BCL 2;

ADULT; AGED; APOPTOSIS; ARTICLE; ASSAY; BENIGN TUMOR; CANCER CELL CULTURE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SIZE; CANCER TISSUE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; REPORTER ASSAY; WESTERN BLOTTING;

AGED; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DNA DAMAGE; DOXORUBICIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84879672675     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1915     Document Type: Article

References (40)

1. Gregory PA, Bracken CP, Bert AG and Goodall GJ: MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle 7: 3112-3118, 2008.
2. Puhr M, Hoefer J, Schafer G, et al: Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am J Pathol 181: 2188-2201, 2012.
3. Sempere LF, Christensen M, Silahtaroglu A, et al: Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 67: 11612-11620, 2007.
4. Childs G, Fazzari M, Kung G, et al: Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am J Pathol 174: 736-745, 2009.
5. Wiklund ED, Bramsen JB, Hulf T, et al: Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer 128: 1327-1334, 2011.
6. Coppola V, De Maria R and Bonci D: MicroRNAs and prostate cancer. Endocr Relat Cancer 17: F1-F17, 2010.
7. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL and Visakorpi T: MicroRNA expression profiling in prostate cancer. Cancer Res 67: 6130-6135, 2007. (Pubitemid 47037493)
8. Schaefer A, Jung M, Mollenkopf HJ, et al: Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 126: 1166-1176, 2010.
9. Chung TK, Cheung TH, Huen NY, et al : Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women. Int J Cancer 124: 1358-1365, 2009.
10. Karaayvaz M, Zhang C, Liang S, Shroyer KR and Ju J: Prognostic significance of miR-205 in endometrial cancer. PLoS One 7: e35158, 2012.
11. Matsushima K, Isomoto H, Yamaguchi N, et al: MiRNA-205 modulates cellular invasion and migration via regulating zinc finger E-box binding homeobox 2 expression in esophageal squamous cell carcinoma cells. J Transl Med 9: 30, 2011.
12. Markou A, Tsaroucha EG, Kaklamanis L, Fotinou M, Georgoulias V and Lianidou ES: Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem 54: 1696-1704, 2008.
13. Wu H, Zhu S and Mo YY: Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res 19: 439-448, 2009.
14. Dar AA, Majid S, de Semir D, Nosrati M, Bezrookove V and Kashani-Sabet M: miRNA-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 protein. J Biol Chem 286: 16606-16614, 2011.
15. Piovan C, Palmieri D, Di Leva G, et al: Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. Mol Oncol 6: 458-472, 2012.
16. Alla V, Kowtharapu BS, Engelmann D, et al: E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73-miR-205 circuitry. Cell Cycle 11: 3067-3078, 2012.
17. Gandellini P, Profumo V, Casamichele A, et al: miR-205 regulates basement membrane deposition in human prostate: implications for cancer development. Cell Death Differ 19: 1750-1760, 2012.
18. Tucci P, Agostini M, Grespi F, et al : Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci USA 109: 15312-15317, 2012.
19. Adachi R, Horiuchi S, Sakurazawa Y, Hasegawa T, Sato K and Sakamaki T: ErbB2 down-regulates microRNA-205 in breast cancer. Biochem Biophys Res Commun 411: 804-808, 2011.
20. Bhatnagar N, Li X, Padi SK, Zhang Q, Tang MS and Guo B: Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis 1: e105, 2010.
21. Fleischmann A, Huland H, Mirlacher M, et al : Prognostic relevance of Bcl-2 overexpression in surgically treated prostate cancer is not caused by increased copy number or translocation of the gene. Prostate 72: 991-997, 2011.
22. Cho IC, Chung HS, Cho KS, et al: Bcl-2 as a predictive factor for biochemical recurrence after radical prostatectomy: an interim analysis. Cancer Res Treat 42: 157-162, 2010.
23. Schaefer A, Jung M, Miller K, et al: Suitable reference genes for relative quantification of miRNA expression in prostate cancer. Exp Mol Med 42: 749-758, 2010.
24. Revelos K, Petraki C, Gregorakis A, Scorilas A, Papanastasiou P and Koutsilieris M: Immunohistochemical expression of Bcl2 is an independent predictor of time-to-biochemical failure in patients with clinically localized prostate cancer following radical prostatectomy. Anticancer Res 25: 3123-3133, 2005.
25. Zuker M: Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 31: 3406-3415, 2003.
26. Martin MM, Buckenberger JA, Jiang J, et al: The human angiotensin II type 1 receptor +1166 A/C polymorphism attenuates microrna-155 binding. J Biol Chem 282: 24262-24269, 2007. (Pubitemid 47328062)
27. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP and Bartel DP: MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 27: 91-105, 2007. (Pubitemid 46991392)
28. Tarasov V, Jung P, Verdoodt B, et al: Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 6: 1586-1593, 2007. (Pubitemid 47327945)
29. Shen Y, Iqbal J, Huang JZ, Zhou G and Chan WC: BCL2 protein expression parallels its mRNA level in normal and malignant B cells. Blood 104: 2936-2939, 2004. (Pubitemid 39434983)
30. Carvalho JR, Filipe L, Costa VL, et al: Detailed analysis of expression and promoter methylation status of apoptosis-related genes in prostate cancer. Apoptosis 15: 956-965, 2010.
31. Gandellini P, Folini M, Longoni N, et al: miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase C epsilon. Cancer Res 69: 2287-2295, 2009.
32. Wright JL SC, Lin DW, Kolb S, et al: Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4+3 and Gleason 3+4 tumors in a population based cohort. J Urol 182: 2702-2707, 2009.
33. Greene SB, Gunaratne PH, Hammond SM and Rosen JM: A putative role for microRNA-205 in mammary epithelial cell progenitors. J Cell Sci 123: 606-618, 2010.
34. Yoshino T, Shiina H, Urakami S, et al: Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res 12: 6116-6124, 2006. (Pubitemid 44703777)
35. Colombel M, Symmans F, Gil S, et al: Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am J Pathol 143: 390-400, 1993. (Pubitemid 24058194)
36. McDonnell TJ, Troncoso P, Brisbay SM, et al: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52: 6940-6944, 1992. (Pubitemid 23006303)
37. Cimmino A, Calin GA, Fabbri M, et al: miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102: 13944-13949, 2005. (Pubitemid 41377683)
38. Hagman Z, Larne O, Edsjo A, et al: miR-34c is down regulated in prostate cancer and exerts tumor suppressive functions. Int J Cancer 127: 2768-2776, 2010.
39. Cole KA, Attiyeh EF, Mosse YP, et al: A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol Cancer Res 6: 735-742, 2008.
40. Cho NY, Kim BH, Choi M, et al: Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features. J Pathol 211: 269-277, 2007. (Pubitemid 46172702)